LDS/Medical Tests/Aspartoacylase (ASPA) Gene Mutation Analysis (Canavan Disease)

Aspartoacylase (ASPA) Gene Mutation Analysis (Canavan Disease)

Canavan disease is an autosomal recessive neuromuscular dystrophy caused by the deficiency of aspartoacylase (ASPA). Mutations in the ASPA gene, encoding the enzyme aspartoacylase, have been associated with Canavan disease. Four ASPA mutations are included in this test: p.Glu285Ala, p.Tyr231X (C>A, C>T), p.Ala305Glu, and c.433-2A>G. The two mutations, p.Glu285Ala and p.Tyr231X, are responsible for 98% of disease-causing alleles in the Ashkenazi Jewish population and 3% in non-Jewish populations. One mutation, p.Ala305Glu, is responsible for 40-60% of disease-causing alleles in non-Jewish populations and approximately 1% in the Ashkenazi Jewish population. The c.433-2A>G is responsible for approximately 1% of disease-causing alleles in the Ashkenzai Jewish population. The disease is characterized by decreased muscle tone, increased head circumference, decreased motor activity and developmental delays by the age of three to five months. Canavan disease symptomatic individuals have a very high concentration of N-acetyl aspartic acid (NAA) in the urine. Couples who are planning a pregnancy or who are already pregnant may decide to have testing to find out if they are carriers and at risk of having a baby with Canavan disease.

  • Diagnosis of Canavan disease
  • Confirmation of diagnosis
  • Carrier testing for at risk individuals
  • Population screening for Ashkenazi Jewish individuals
  • Prenatal diagnosis for at risk individuals
Four mutations are analyzed: Y231X(C>A), E285A, A305E, 433(-2)A>G. Any of these heterozygous mutations would indicate patient is a carrier. Compound heterozygous and homozygous of any of these four mutations indicates or confirms disease.

Negative for mutation analyzed. Negative for N-acetylaspartic acid (NAA) in urine and amniotic fluid. 

 

 

Gas chromatography-mass spectrometry (GC-MS) used for measurement of the concentration N-acetylaspartic acid (NAA) in urine and amniotic fluid. Targeted mutation analysis, DNA sequencing analysis, Next Generation Sequencing, Ral-time PCR and Allele Specific Primer Extension or ARMS.

Urine, Skin fibroblasts, Whole blood collected in lavender top tube (EDTA), prenatal specimens: Amniotic fluid or chorionic villi (CV).

Transport of all specimens refrigerated at 4°C.

Stability (blood)

  • Ambient: 1-3 days
  • Refrigerated: 7-14 days
Ashkenazi Jewish Panel, Blood chemistry panel, Urine chemistry panel, CSF chemistry panel.
1-2 weeks
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login